EXECUTIVE COMMITTEE MEMBERS, DEPARTMENT/PROGRAMME COORDINATORS and SCIENTIFIC COMMITTEE MEMBERS

DISCLOSURE OF POTENTIAL CONFLICT OF INTEREST 2020

ESO’s initiatives and activities are defined by the ESO Executive Committee, the Scientific Committee and by the Department/Programme Coordinators. For transparency, the ESO core collaborators declare potential conflict of interest that might rise in general when programmes are defined and developed.

We consider as potential conflict of interest any of the following:

 Active role in committees or at managerial level with other organisations.  Any financial interest in or arrangement with a company whose products or services might be involved when proposing an activity, or included in the contents of a proposed activity  Any financial interest in or arrangement with a competing company.  Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in proposing and developing activities, including pertinent commercial or other sources of funding for the person or for the associated department or organisation, personal relationships or direct academic competition.

Adriana Albini: Besides non-profit grants (POR with Campania region for preventive drugs from the Sea) she has research funding from the Food Small Company LaVialla for studies on olive oil derivatives. She is a reviewer for ERC (paid expert). She is editor of Cancerworld journal

Regina Beets Tan: No significant relationships

Felipe A. Calvo: No significant relationships

Fatima Cardoso: Receipt of honoraria or consultation fees from Amgen, Astellas/Medivation, Astra Zeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck- Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, priME Oncology, Roche, Samsung Bioepis, Sanofi, Seattle Genetics, Teva

Paolo Casali: His institution received funds for research from Advenchen Laboratories, Amgen Dompé, AROG Pharmaceuticals, Bayer, Blueprint Medicines, Daiichi Sankyo, Deciphera, Eli Lilly, Epizyme Inc., Glaxo, Karyopharm Pharmaceuticals, Novartis, Pfizer, PharmaMar. Receipt of honoraria for speaker, consultancy or advisory role from Bayer, Deciphera, Eisai, Eli Lilly, Nektar Therapeutics, Pfizer

Franco Cavalli: No significant relationships

Alberto Costa: No significant relationships Tanja Cufer: Receipt of honoraria or consultation fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Roche, MSD, Pfizer and Takeda

Alessandra Curioni: Receipt of honoraria or consultation fees from Astra Zeneca; BMS, Boehringer Ingelheim, MSD, Pfizer, Roche, Takeda. Spouse/partner: IBM (no direct conflict of interest)

Maria Del Grande: Honoraria: AstraZeneca (advisory board) Alexandru Eniu: Receipt of grants/research supports from Astra Zeneca, Roche, Celltrion, Pfizer, Novartis

Leslie Fallowfield: Receipt of grants/research supports from Nanostring, GSK. Receipt of honoraria or consultation fees from Genomic Health, Myriad, Nanostring, Roche, Lilly, AstraZeneca, Puma & Novartis

Enriqueta Felip Font: Receipt of grants/research supports from Fundación Merck Salud, grant from Oncology Innovation (GOI). Advisory/Consultancy: Pfizer, Roche, Boehringer Ingelheim, Astra Zeneca, Bristol Myers, Squibb, Guardant Health, Novartis, Takeda, Abbvie, Blue Print Medicines, Lilly, Merck KGaA, Merck Sharp & Dohme, Janssen, Samsung. Participation in a sponsored speakers’ bureau of Pfizer, Roche, Astra Zeneca, Bristol Myers Squibb, Novartis, Takeda, Lilly, Merck Sharp & Dohme, Medscape, priME Oncology, Touch Time. Other support: GRÌFOLS (independent board member)

Silke Gillessen Sommer: Honoraria: Janssen. Consulting or Advisory Role: Astellas Pharma (Inst), Curevac (Inst), Novartis (Inst), Active Biotech (Inst), Bristol-Myers Squibb (Inst), Ferring (Inst), MaxiVax, Advanced Accelerator Applications, Roche, Janssen (Inst), Innocrin Pharma (Inst), Sanofi, Bayer (Inst), Orion Pharma GmbH, Clovis Oncology (Inst), Menarini Silicon Biosystems (Inst) Patents, Royalties, Other Intellectual Property: Method for biomarker (WO 3752009138392 A1). Other Relationship: Nektar, ProteoMediX

Joseph Gligorov: Receipt of grants/research supports: Eisai, Genomic Health, Novartis, Pfizer, Roche Genentech. Receipt of honoraria or consultation fees: Daiichi, Eisai, Genomic Health, Ipsen, Macrogenics, MSD, Mylan, Novartis, Onxeo, Pfizer, Roche Genentech. Participation in a sponsored speakers’ bureau: Eisai, Genomic Health, Ipsen, Mylan, Novartis, Pfizer, Roche Genentech

Stan Kaye: No significant relationships

Holger Moch: Receipt of grants/research supports: Roche. Receipt of honoraria or consultation fees: Roche, Amgen, Merck, Ipsen, Bayer

Peter Naredi: No significant relationships

Olivia Pagani: Receipt of honoraria or consultation fees: Takeda, Pfizer, Novartis, Roche, Ipsen, Eli Lilly

Dimitrios Papamichael: Receipt of grants/research supports: MSD. Receipt of honoraria or consultation fees: Merck Serono, Roche, Novartis. Participation in a sponsored speakers’ bureau: Merck Serono, Amgen. Other support (please specify): ESMO GI Faculty, ESMO Membership Committee, SIOG Scientific Committee, ESMO/SIOG Working Group Co-Chair.

Nicholas Pavlidis: No significant relationships

Fedro Peccatori: Receipt of honoraria or consultation fees: Roche, Astra Zeneca, Ipsen. Participation in a sponsored speakers’ bureau: PrIME Oncology

Christian Rolfo: Not received

Cristiana Sessa: No significant relationships

Lena Sharp: No significant relationships

Marco Siano: Receipt of honoraria or consultation fees: MSD, BMS Merck, Astra Zeneca. Other support (please specify): travel: sanofi, roche, MSD

Stephan Stilgenbauer: Receipt of grants/research supports: AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. Receipt of honoraria or consultation fees: AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. Participation in a sponsored speakers’ bureau: AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis

Eric Van Cutsem: Receipt of grants/research supports: Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Roche, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier paid to his institution. Receipt of honoraria or consultation fees: Array, Astrazeneca, Bayer, Biocartis, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Pierre-Fabre, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier, Sirtex, Taiho

Emanuele Zucca: Receipt of grants/research supports: Celgene, Roche, Janssen, Merck, AcertaPharma, Morphosys. Receipt of honoraria or consultation fees: Celgene, Roche, Celltrion Helthcare, Mei Pharma, AstraZeneca. Other support (please specify): Travel Expenses: Abbvie, Gilead, Roche / Expert Statements and Meetings: Gilead, Bristol Myers Squibb, MSD